Description

Actemra Injection For Arthritis

Actemra Injection is used to treat adults with moderately to severely active rheumatoid arthritis (RA) after at least one other medicine called a disease-modifying antirheumatic drug (DMARD) has been used and has not worked well.

Actemra (tocilizumab) is an interleukin-6 (IL-6) receptor inhibitor used to treat moderate to severe rheumatoid arthritis in children and adults. To treat adults with giant cell arteritis (GCA)

Buy Similar Products

Actemra Injection Uses

Actemra is indicated for the treatment of:

• Rheumatoid arthritis (RA) Adult patients who have moderately to severely active rheumatoid arthritis and who have tried one or more disease-modifying antirheumatic drugs (DMARDs) but have had an inadequate response to them.
• Giant cell arteritis (GCA) Adult patients with giant cell arteritis.
• Systemic sclerosis-associated interstitial lung disease (SSc-ILD) Adult patients with systemic sclerosis-associated interstitial lung disease to slow the rate of decline in lung function.
• Polyarticular juvenile idiopathic arthritis (PJIA) Patients 2 years of age and older who have active polyarticular juvenile idiopathic arthritis.
• Systemic juvenile idiopathic arthritis (SJIA) Patients 2 years of age and older who have active systemic juvenile idiopathic arthritis.
• Cytokine release syndrome (CRS) Adults and pediatric patients 2 years of age and older who have severe or life-threatening cytokine release syndrome induced by chimeric antigen receptor (CAR) T cells.
• COVID-19: Approved by the FDA for adult patients who are hospitalized with COVID-19 and who receive systemic corticosteroids and require supplemental oxygen, invasive or non-invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).
• COVID-19: Emergency use authorization for pediatric patients (ages 2 years to less than 18 years) with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, invasive or non-invasive mechanical ventilation, or ECMO.

Actemra Injection Dose

Your doctor will give you Actemra once every four weeks by intravenous (IV) infusion. Actemra can be taken with or without methotrexate (or other DMARDs).

How Long Does It Take For Actemra Injections To Work

The individual results can change. ACTEMRA IV infusions, taken without methotrexate, started working in as little as 2 weeks in some patients.

Actemra Injection Side Effects

Actemra may cause serious side effects including:

• severe stomach cramps,
• swelling,
• diarrhea,
• constipation,
• nosebleeds,
• bleeding gums,
• abnormal vaginal bleeding,
• any bleeding that does not stop,
• blood in urine or stool,

Actemra Injection Ingredients

Tocilizumab (TCZ) is a recombinant humanized anti-human monoclonal antibody of the immunoglobulin G1k subclass directed against soluble and membrane-bound interleukin 6 receptors (IL-6R). It is marketed in the European Union (EU) under the trade name RoActemra and in the United States as Actemra.

Frequently Asked Questions About Actemra Injection

Q: Is ACTEMRA injection safe?
A: Serious allergic reactions, including death, can occur with ACTEMRA. Tell your healthcare provider before your next dose if you had hives, rash, or redness after the injection.

Q: Is ACTEMRA a steroid?
A: It is important to note that ACTEMRA is not a steroid. It is a biological. A biologic is a type of medicine developed through processes similar to those that occur naturally in the body.

Q: Why is ACTEMRA so expensive?
A: Actemra contains the active ingredient tocilizumab and is available only as a brand-name biologic drug. It does not come in a biosimilar version.